ID   SK-MEL-93 DX-1
AC   CVCL_5651
AS   CVCL_3879; CVCL_U902
SY   SK-MEL-93-DX-1; SK-MEL-93 DX1; SK-MEL-93 (DX1); DX-1; DX1; SK-MEL-93(1); SK-MEL-93-1; SK-MEL-93; SK-Mel-93; SK-MEL93; SKMel-93; SKMEL93; SKMel93
DR   BTO; BTO_0002968
DR   Cosmic; 721816
DR   Cosmic; 926000
DR   Cosmic; 933119
DR   Cosmic; 1060426
DR   Wikidata; Q54954338
RX   PubMed=2886213;
RX   PubMed=6864164;
RX   PubMed=6976407;
RX   PubMed=7017212;
RX   PubMed=7175440;
RX   PubMed=9598804;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous (PubMed=9598804).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
CC   Derived from site: Metastatic; Left thigh, hypodermis; UBERON=UBERON_0000376+UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5652 ! SK-MEL-93 DX-2
OI   CVCL_5650 ! SK-MEL-93 DX-3
OI   CVCL_A432 ! SK-MEL-93 DX-4
OI   CVCL_A433 ! SK-MEL-93 DX-5
OI   CVCL_A434 ! SK-MEL-93 DX-6
OI   CVCL_A435 ! SK-MEL-93 DX-B
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 17
//
RX   PubMed=2886213;
RA   Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.;
RT   "Loss of heterozygosity at autosomal and X-linked loci during tumor
RT   progression in a patient with melanoma.";
RL   Cancer Res. 47:3995-4000(1987).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=6976407; DOI=10.1084/jem.154.6.1764; PMCID=PMC2186539;
RA   Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Heterogeneity in surface antigen and glycoprotein expression of cell
RT   lines derived from different melanoma metastases of the same patient.
RT   Implications for the study of tumor antigens.";
RL   J. Exp. Med. 154:1764-1778(1981).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=7175440; DOI=10.1084/jem.156.6.1755; PMCID=PMC2186870;
RA   Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.;
RT   "Surface antigens of melanocytes and melanomas. Markers of melanocyte
RT   differentiation and melanoma subsets.";
RL   J. Exp. Med. 156:1755-1766(1982).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//